J
Janet M. Wolter
Researcher at University of Texas MD Anderson Cancer Center
Publications - 4
Citations - 10943
Janet M. Wolter is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Metastatic breast cancer & Trastuzumab. The author has an hindex of 3, co-authored 3 publications receiving 10321 citations.
Papers
More filters
Journal ArticleDOI
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon,Brian Leyland-Jones,Steven Shak,Hank Fuchs,Virginia E. Paton,Alex Bajamonde,Thomas Fleming,Wolfgang Eiermann,Janet M. Wolter,Mark D. Pegram,José Baselga,Larry Norton +11 more
TL;DR: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
Journal ArticleDOI
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Aman U. Buzdar,Walter Jonat,Anthony Howell,Stephen E. Jones,Carl Blomqvist,Charles L. Vogel,Wolfgang Eiermann,Janet M. Wolter,Mohammed Azab,Alan Webster,Paul V. Plourde +10 more
TL;DR: Anastrozole, 1 and 10 mg once daily, is well tolerated and as effective as megestrol acetate in the treatment of postmenopausal women with advanced breast cancer who progressed following tamoxifen treatment.
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Melody A. Cobleigh,Charles L. Vogel,Debu Tripathy,Nicholas J. Robert,Suzy Scholl,Louis Fehrenbacher,Janet M. Wolter,Virginia E. Paton,Steven Shak,Gracie Lieberman,Dennis J. Slamon +10 more
TL;DR: In this article , the effectiveness and safety of recombinant humanized anti-HER2 monoclonal antibody as a single agent was evaluated in women with metastatic breast cancer that had progressed after chemotherapy for metastatic disease.
Journal ArticleDOI
Clinical benefit of trastuzumab (H) among patients with HER2-positive metastatic breast cancer (MBC) not achieving objective responses when treated with H plus chemotherapy (CT)
C. H. Yeon,DJ Slamon,Ravindranath Patel,A. Cartmell,Brian Leyland-Jones,Pamela M. Klein,Wolfgang Eiermann,Janet M. Wolter,Gracie Lieberman,Mark D. Pegram +9 more
TL;DR: A retrospective analysis of the subset of patients not achieving an OCR from the pivotal phase III clinical trial of CT with or without H in women with MBC found mechanisms of action of H may not result in OCR, but rather induce disease stabilization.